Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran for the Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy
Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran for Hereditary Angioedema
Finlay Minerals completes Field Work on Newly Identified Geophysical Targets on the SAY and JJB Properties
Aventis Energy Confirms Strong Radioactivity During Successful Exploration Program at the Corvo Uranium Project
